NCT00131937View on ClinicalTrials.gov

Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

September 30, 2011

Study Completion Date

August 31, 2012

Conditions
Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions
DRUG

sorafenib tosylate

Given orally

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00131937 - Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter